AU2020205042B2 - An A3 adenosine receptor ligand for use for achieving a fat loss effect - Google Patents

An A3 adenosine receptor ligand for use for achieving a fat loss effect Download PDF

Info

Publication number
AU2020205042B2
AU2020205042B2 AU2020205042A AU2020205042A AU2020205042B2 AU 2020205042 B2 AU2020205042 B2 AU 2020205042B2 AU 2020205042 A AU2020205042 A AU 2020205042A AU 2020205042 A AU2020205042 A AU 2020205042A AU 2020205042 B2 AU2020205042 B2 AU 2020205042B2
Authority
AU
Australia
Prior art keywords
ligand
subject
a3ar
amine
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020205042A
Other languages
English (en)
Other versions
AU2020205042A1 (en
Inventor
Shira Cohen
Motti FARBSTEIN
Pnina Fishman
Inbal ITZHAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of AU2020205042A1 publication Critical patent/AU2020205042A1/en
Application granted granted Critical
Publication of AU2020205042B2 publication Critical patent/AU2020205042B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020205042A 2019-01-06 2020-01-05 An A3 adenosine receptor ligand for use for achieving a fat loss effect Active AU2020205042B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL264112 2019-01-06
IL264112A IL264112A (en) 2019-01-06 2019-01-06 An a3 adenosine receptor ligand for use for reducing level of adipocytes
PCT/IL2020/050011 WO2020141535A1 (en) 2019-01-06 2020-01-05 An a3 adenosine receptor ligand for use for achieving a fat loss effect

Publications (2)

Publication Number Publication Date
AU2020205042A1 AU2020205042A1 (en) 2021-07-15
AU2020205042B2 true AU2020205042B2 (en) 2024-10-10

Family

ID=65656120

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020205042A Active AU2020205042B2 (en) 2019-01-06 2020-01-05 An A3 adenosine receptor ligand for use for achieving a fat loss effect

Country Status (11)

Country Link
US (1) US12213990B2 (https=)
EP (1) EP3906034A1 (https=)
JP (3) JP2022517753A (https=)
KR (1) KR20210113279A (https=)
CN (1) CN113543790A (https=)
AU (1) AU2020205042B2 (https=)
BR (1) BR112021013084A2 (https=)
CA (1) CA3126002A1 (https=)
IL (2) IL264112A (https=)
MX (1) MX2021008172A (https=)
WO (1) WO2020141535A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300014340A1 (it) * 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017090036A1 (en) * 2015-11-23 2017-06-01 Can-Fite Biopharma Ltd. An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
KR101881441B1 (ko) * 2017-01-20 2018-07-24 서울대학교산학협력단 다중 약리단 특성에 기반한 비정상적 아디포넥틴 관련 질환 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
DE69428536T2 (de) 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CN101410114B (zh) 2006-01-26 2012-07-04 美国政府卫生与公共服务部 A3腺苷受体别构调节剂
EP2608794A4 (en) * 2010-08-26 2014-01-22 Univ Northeastern METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING OIL CONTAINER
CN104159589A (zh) 2012-01-23 2014-11-19 坎-菲特生物药物有限公司 肝脏状况的治疗

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017090036A1 (en) * 2015-11-23 2017-06-01 Can-Fite Biopharma Ltd. An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
KR101881441B1 (ko) * 2017-01-20 2018-07-24 서울대학교산학협력단 다중 약리단 특성에 기반한 비정상적 아디포넥틴 관련 질환 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KR 101881441 B1 (Machine translation reviewed) *

Also Published As

Publication number Publication date
IL264112A (en) 2020-07-30
WO2020141535A1 (en) 2020-07-09
JP2023100928A (ja) 2023-07-19
IL284463B1 (en) 2026-04-01
IL284463A (en) 2021-08-31
JP2022517753A (ja) 2022-03-10
KR20210113279A (ko) 2021-09-15
CA3126002A1 (en) 2020-07-09
EP3906034A1 (en) 2021-11-10
JP2025098147A (ja) 2025-07-01
MX2021008172A (es) 2021-08-11
AU2020205042A1 (en) 2021-07-15
US20220079968A1 (en) 2022-03-17
CN113543790A (zh) 2021-10-22
US12213990B2 (en) 2025-02-04
BR112021013084A2 (pt) 2021-09-21

Similar Documents

Publication Publication Date Title
US11033543B2 (en) Methods of providing weight loss therapy in patients with major depression
WO2008023362A2 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
US11291681B2 (en) Method for treating fibrotic liver tissue using Cl-IB-MECA
KR20090032083A (ko) 신장 기능이 손상된 개체의 이뇨 작용 개선 방법
KR101826690B1 (ko) 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
JP2025098147A (ja) 脂肪減少効果の達成に使用するためのａ３アデノシン受容体リガンド
EP3530273B1 (en) A3 adenosine receptor ligands for use in the treatment of a sexual dysfunction
HK40062237A (en) A3 adenosine receptor ligand for use for achieving a fat loss effect
HK40011453A (en) A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
HK1261991A1 (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
HK1261991B (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
BR112015002697B1 (pt) Uso de n6-(3-iodobenzil)-adenosina-5'-n-metiluronamida ou n-(3,4- dicloro-fenil)-2- ciclohexil-1h-imidazo[4,5-c]quinolin-4-amina

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)